The 6 most recent market catalysts affecting $CMPX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 55
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4
Citizens analyst Reni J. Benjamin maintained a 'Market Outperform' rating on Compass Therapeutics (CMPX) but drastically cut the price target from $10 to $4. This significant reduc…
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 75
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1
Wedbush's downgrade of Compass Therapeutics from Outperform to Neutral, coupled with a drastic reduction in the price target from $5 to $1, signals a significant loss of confidence…
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 95
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
Compass Therapeutics (CMPX) experienced a massive sell-off after the FDA recommended a survival benefit trial for its lead cancer drug, tovecimig, before it can submit a Biologics …
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6
Piper Sandler analyst Biren Amin has maintained an 'Overweight' rating on Compass Therapeutics (CMPX) and raised the price target from $4 to $6. This action signals increased confi…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate
Compass Therapeutics (CMPX) announced Q2 losses of $(0.13) per share, which missed the analyst consensus estimate of $(0.11) by 18.18%. This is a significant event as earnings miss…
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 65
Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress
Compass Therapeutics announced the acceptance of an abstract for an oral presentation at the European Society for Medical Oncology (ESMO) Congress in October 2026. This is a positi…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.